Inhibition of angiogenesis
US5001116A · kind A · utility
134Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 1989 |
| Grant date | Mar 19, 1991 |
| Priority date | — |
| Expiry date | May 17, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/715
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Angiogenesis in mammals is inhibited by administration of the active agents (1) heparin or a heparin fragment which is a hexasaccharide or larger or analogous compounds and (2) a steroid having 17.alpha.- and 21-hydroxy groups, 3- and 20-one groups, and in the 16-position hydrogen hydroxy or a methyl group, and non-toxic physiologically acceptable carboxylates, acetals, ketals and phosphates thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.